---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-22-003581"
form_type: "8-K"
ticker: "PGEN"
cik: "0001356090"
company_name: "PRECIGEN, INC."
filed_at: "2022-03-01T23:59:59+00:00"
generated_at: "2026-06-27T02:52:37.728717+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Precigen Q4 net loss $25M, FY loss $96.8M; $163.7M cash; clinical progress

## Summary
- Q4 net loss from continuing ops $25.0M ($0.13/sh) vs $39.7M ($0.22/sh) year ago; full-year net loss $96.8M ($0.49/sh) vs $103.8M.
- Cash, cash equivalents and investments totaled $163.7M as of Dec 31, 2021; net cash used in ops $55.8M in 2021, down from $77.0M in 2020.
- January 2021 public offering of 17.25M shares raised gross proceeds of ~$129.4M; cash expected to fund operations well into 2023.
- Clinical milestones: completed enrollment in PRGN-3006 AML, PRGN-3005 ovarian, and PRGN-2012 RRP studies; IND clearances for PRGN-3007 and PRGN-2012.
- R&D expenses up 20% for the year; SG&A down 19%; non-core businesses (Trans Ova, Exemplar) increased revenues and profitability.

## SEC filing metadata
- accession: 0000950103-22-003581
- form_type: 8-K
- ticker: PGEN
- cik: 0001356090
- company_name: PRECIGEN, INC.
- filed_at: 2022-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356090/000095010322003581/0000950103-22-003581-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356090/000095010322003581/dp168191_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-22-003581
- JSON: https://secwatch.observer/filing/0000950103-22-003581.json
- Plain text: https://secwatch.observer/filing/0000950103-22-003581.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.